Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Cxbladder's Clinical Utility to be in Focus at the American Urological Association's Annual Meeting (AUA 2025)


News provided by

Cxbladder’s clinical

Apr 23, 2025, 07:00 ET

Share this article

Share toX

Share this article

Share toX


Recognition of Cxbladder's clinical and economic value in evaluating patients presenting with hematuria is set to gain momentum at the American Urological Association's (AUA) Annual Meeting, April 26–29 in Las Vegas.

HERSEY, Pa., April 23, 2025 /PRNewswire-PRWeb/ -- Recognition of Cxbladder's clinical and economic value in evaluating patients presenting with hematuria is set to gain momentum at the American Urological Association's (AUA) Annual Meeting, April 26–29 in Las Vegas.

A plenary session at the meeting will highlight Cxbladder Triage's inclusion in the AUA's new microhematuria guideline released in February 2025. Additional sessions will cover a large real-world study by Kaiser Permanente[1] confirming the clinical utility of Triage, and preliminary results[2] from the DRIVE study focused on the clinical validation of Triage Plus. These sessions are a significant opportunity for Pacific Edge to deepen market understanding of Cxbladder's performance and drive its broader clinical adoption.

A plenary session at the meeting will highlight Cxbladder Triage's inclusion in the AUA's new microhematuria guideline released in February 2025

Post this

Pacific Edge Chief Executive Dr Peter Meintjes said: "Guideline amendments are always significant talking points at an AUA meeting. However, with urine biomarkers getting their first positive inclusion language in the microhematuria guideline[3] and Cxbladder Triage being the first and only biomarker to receive a 'Grade A'[4] evidence, this year is bigger than most, and the plenary session provides a great platform for how Pacific Edge is improving the standard of patient care.

"The Kaiser Permanente study is important because it demonstrates the real-world impact of Cxbladder Triage with tremendous statistical power given the sample size of 3,353 patients. The design of the study prospectively managed hematuria patients according to the new Triage-based standard of care and then retrospectively compared those clinical outcomes to a cohort of "risk-matched" patients from Kaiser Permanente nation-wide EMR who did not. This kind of study and evidence generation is uniquely available in the Kaiser Permanente system and underscores the value of our partnership and our shared commitment to improving patient outcomes.

"The DRIVE study will be presented in the Urological Society of American Veterans (USAV) session at the AUA to showcase preliminary clinical validity results for Triage Plus for the evaluation of hematuria in a Veterans population. These data are important for establishing a local coverage determination for Triage Plus with Novitas, and as validation for the US Veterans Administration to consider incorporating Cxbladder into its facilities."

Further detail on the AUA 2025 sessions is below:

Key Milestone: Cxbladder Triage Incorporated into AUA Microhematuria Guideline

The highlight for Pacific Edge and Cxbladder will be the Plenary: Afternoon Session (Saturday April 26, 1:20–1:50 PM) where leading urologists will discuss the new AUA Microhematuria Guideline, which for the first time incorporated language for the use of urine-based biomarkers for intermediate-risk patients.

The new guideline says urologists may use urine-based biomarkers for appropriately counseled intermediate-risk patients presenting with microhematuria to assist their decision on whether to defer a cystoscopy. It specifically mentions Cxbladder Triage as the only urine-based biomarker test that has 'Grade A' evidence from a randomized controlled trial — the STRATA Study[5], which demonstrated the test can reduce cystoscopies by up to 59% without compromising tumor detection.

The session will be led by Vanderbilt University Medical Center Professor Daniel Barocas, Mayo Clinic Professor of Urology Stephen Boorjian — who are both members of the guideline panel — as well as University of Virginia Professor of Urology Tracy Downs and University of North Carolina, Chapel Hill, Associate Professor of Urology & Co-Director Urologic Oncology Mary Westerman.

Kaiser Permanente Real-World Data Validates Cxbladder's Clinical Utility and Safety

A second key presentation at the meeting will be delivered during the Bladder Cancer: Epidemiology & Evaluation I session (Saturday, April 26, 1:00–3:00 PM). The study by Kaiser Permanente Southern California reinforced existing evidence on the Clinical Utility of Cxbladder Triage, in safely reducing patients presenting with hematuria from unnecessary cystoscopies.

The retrospective study compared the new clinical pathway that includes evaluation of microhematuria patients with Cxbladder Triage to inform the decision to offer the patient a cystoscopy and imaging. It matched 3,353 Kaiser patients that received Triage, with an equal number of patients with similar risk that received the prior standard of care without Cxbladder Triage. The primary endpoints were to compare the number of cystoscopies and imaging procedures between the new standard of care incorporating Triage and the prior standard of care that did not.

The study found:

  • In patients with 'Low Probability' Triage scores, the cystoscopy rate was 3.8% versus 46.5% in the standard of care patients.
  • In patients with 'High Probability' Triage scores, the cystoscopy rate was 73.4% versus 45.7% in the standard of care patients.
  • The overall bladder cancer detection rate between the Triage patients and the standard of care patients was similar.

The authors of the study concluded: "These data reveal that Cxbladder Triage testing resulted in significantly decreased cystoscopy and imaging utilization in those classified as low risk without any negative patient outcomes, while simultaneously demonstrating increases in the cystoscopy and bladder cancer detection rate in the physician directed protocol group."

The DRIVE Study Expands Evidence Base for Cxbladder Triage Plus

The Clinical Validation of Cxbladder Triage Plus[6] in a Veterans population will be presented at the Urological Society for American Veterans meeting on Monday, April 28 (7:30 AM–12:00 PM) by one of the study's investigators Dr Kyoko Sakamoto of the San Diego VA medical center.

The DRIVE Study (Detection and Risk Stratification In Veterans Presenting with Hematuria) evaluated the prognostic performance of Cxbladder Triage Plus compared to cystoscopy. It showed that Triage Plus demonstrated similarly high-performance characteristics in the veterans' population when compared with the proof-of-concept study by Lotan et al. in 2022[7].

The authors of the study concluded: "Cxbladder Triage Plus demonstrated clinical validity in this VA population with gross hematuria or microhematuria, with high sensitivity and specificity. These findings indicate that Triage Plus may be safely used to rule out or detect [urothelial cancer] in patients with hematuria."

The Cxbladder Team looks forward to speaking with all of those clinicians who are planning to attend AUA 2025 and invites them to visit the Cxbladder booth (#2239). For any questions in the lead up to the event, please contact the Team at [email protected].

[1] Loo R.K., et al (2025) Clinical Utility of a Urine Biomarker (Cxbladder Triage) Compared to a Standard of Care for Microscopic Hematuria Evaluations in a Large Independent Delivery Network. Abstract submitted to the AUA 2025 meeting.

[2] Savage S.J., et al (2025) The Prognostic Performance of Cxbladder Triage Plus for the Identification and Priority Evaluation of Veterans at Risk for Urothelial Carcinoma: The Drive Study, Abstract submitted to the AUA 2025 meeting.

[3] Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. doi: 10.1097/JU.0000000000004490.

[4] The AUA defines 'Grade A' evidence as evidence with a high certainty rating and notes evidence of this grade makes it "very confident that the true effect lies close to that of the estimate of the effect."

[5] Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.

[6] Cxbladder Triage Plus is a next generation Cxbladder UBTM test that combines an analysis of mRNA and DNA markers to further improve clinical utility and efficiency. As a single test for hematuria evaluation, Triage Plus is optimized for the risk stratification of patients presenting with microhematuria. Timing for the launch of Cxbladder Triage Plus in countries across the Asia Pacific Region is to be confirmed. For more information, please contact us at [email protected].

[7] Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. The Journal of Urology, 10-1097.

Media Contact

Peter Meintjes (CEO), Pacific Edge, 1 203 947 2772, [email protected], https://www.pacificedgedx.com/ 

SOURCE Cxbladder’s clinical

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.